Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
SIB-CRT in LARC: 9yr OS 74.3% vs 48.9% (HR 0.43, P=0.008) with a 56Gy PGTV boost, despite identical pCR (15.2% vs 18.4%).
One lower-GI readout: a 106-pt randomized phase 2 says a simultaneous integrated boost to 56Gy buys 9-year OS, DFS, MFS and LC, but pCR did not move, so the mechanism for a ~25-point OS split is unexplained and MFS (HR 0.48) tracks LC (HR 0.40) too closely for a pelvic boost alone. Hypothesis-generating for dose escalation in chemo-naive LARC, not yet a reason to leave 50Gy/25fx.
read the full digest →Studies · 117
- SIB-CRT vs Standard CRT for LARC (NCT02195141)9yr OS 74.3% vs 48.9% (HR 0.43, P=0.008) with SIB dose escalation to 56Gy PGTV, despite identical pCR.
- IROCK Contouring GuidelinesFirst international consensus contouring guideline for RCC SABR; median DSC 0.85 across 4 cases, 16 radiation oncologists.
- Dose-Escalated RT for MIBC (TMT)SHR 0.20 (0.05-0.89) for invasive local recurrence with SIB dose escalation in TMT; no OS or MFS difference.
- Immune Cell Sparing RTALC reduction improved 13.4% (95% CI 2.8-24.0, p=0.01) with immune-sparing SBRT planning vs standard, 29.5% in central tumors.
- GÖTEBORG-1PC-specific survival 94% at 25yr on active surveillance, but failure-free survival fell to 68% at 22yr.
- POSEIDONOS HR 0.87 (0.76-1.01), p=0.06 adding hormone therapy to postop RT; 0.7% absolute at 10y, PSA-dependent interaction p=0.02.
- DBCG Skagen Trial 13y arm lymphedema 8.0% (40Gy/15fx) vs 9.4% (50Gy/25fx), OR 0.84, noninferior; LRR, distant recurrence, and mortality all equivalent.
- PACE-B5yr PROMs comparable for SBRT vs conventional RT: pad-free 91% vs 90%, mod/big urinary leak 6% vs 4%, bowel bother 5% both arms.
- ESTRO Prostate SBRT Consensus Recommendations15-expert ESTRO Delphi consensus on optimising primary prostate SBRT: patient selection, contouring, dose/fractionation, follow-up, and delivery technique.
- ProtecT (secondary analysis: cribriform morphology)Cribriform-negative pts (87%): radical Rx gave no significant 15yr metastasis reduction vs active monitoring; cribriform-negative GG2 matched GG1 risk.
- NRG Oncology/RTOG 0848OS primary EP not met (HR 0.96, 90% CI 0.79-1.18) adding adjuvant CXRT to gemcitabine; node-negative subgroup OS benefit on interaction (P=.0063).
- TROG 08.03 RAVES QOL SubstudyAt 5yr, 16% vs 2% severe urinary leakage aRT vs no RT (p=0.01); sRT timing had no QOL effect.